The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...
The Food and Drug Administration approved Vertex Pharmaceuticals’ “Journavx” on Thursday, greenlighting the non-opioid ...
A new non-opioid painkiller, JournaVX, has received approval from the FDA, marking the first new type of pain medication in ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...